WebMay 14, 2024 · CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 2/3 XIRIUS study of … Web21 hours ago · Dive Brief: Biogen has agreed to license a program from Denali Therapeutics, with the aim of creating therapies for Alzheimer’s disease that are safer or more effective. The program is part of Denali’s “transport vehicle” platform, which uses drugmaking technology to shepherd large therapeutic molecules like antibodies across …
Biogen opts into Denali Alzheimer’s program targeting amyloid …
WebMay 11, 2024 · In its latest investment into the field of gene therapy, Biogen has licensed technology that it believes could help create new treatments for central nervous system … WebMay 14, 2024 · In addition to Biogen’s gene therapy candidates for various ophthalmic conditions, the company also entered into an agreement with Catalyst Biosciences to develop and commercialize pegylated CB ... diabetes education and telehealth
Biogen and Sangamo Announce Global Collaboration to Develop …
WebTofersen was shown to reduce levels of the SOD1 protein in cerebral spinal fluid by 35% as early as eight weeks after participants began receiving the therapy. By 12-16 weeks, tofersen reduced bloodstream levels of NfL, a biomarker of neuron damage and neurodegeneration, by 50%. These biomarker changes were subsequently reflected in … WebAs a patient of a Biogen treatment or therapy, you have the option of being connected to a Biogen support coordinator who can help answer any questions you may have about treatment and provide one-on-one phone support. Biogen Support Services is also here to provide help with financial assistance, navigating insurance, or learning more about ... WebJan 4, 2024 · A second treatment, the Zolgensma gene therapy from Novartis, became available in 2024. Then a third option arrived the following year with Evrysdi, an oral medication developed by Roche. On its most recent earnings report, Biogen pointed to this more crowded market as the main reason why third quarter Spinraza revenue in the U.S. … diabetes education and support